Another rival is Sanofi’s long-acting FVIII replacement therapy Altuviiio (efanesoctocog alfa), which also offers once-weekly dosing. Haemophilia B is likely to be the greatest opportunity for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...

Please find enclosed communication for the attention of the shareholders of the Company for Apportionment of Cost of Acquisition of Equity Shares of Sanofi India Limited and Sanofi Consumer Healthcare ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,385.85 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...